Literature DB >> 12743698

Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage.

G Gao1, C Shao, S X Zhang, A Dudley, J Fant, J-X Ma.   

Abstract

AIMS/HYPOTHESIS: Kallikrein-binding protein (KBP) is a serine proteinase inhibitor (serpin). It specifically binds to tissue kallikrein and inhibits kallikrein activity. Our study was designed to test its effects on retinal neovascularization and vascular permeability.
METHODS: Endothelial cell proliferation was determined by [(3)H] thymidine incorporation assay and apoptosis quantified by Annexin V staining and flow cytometry. Effect on retinal neovascularization was determined by fluorescein angiography and count of pre-retinal vascular cells in an oxygen-induced retinopathy (OIR) model. Vascular permeability was assayed by the Evans blue method. Vascular endothelial growth factor (VEGF) was measured by Western blot analysis and ELISA.
RESULTS: Kallikrein-binding protein specifically inhibited proliferation and induced apoptosis in retinal capillary endothelial cells. Intravitreal injection of KBP inhibited retinal neovascularization in an OIR model. Moreover, KBP decreased vascular leakage in the retina, iris and choroid in rats with OIR. Blockade of kinin receptors by specific antagonists showed significantly weaker inhibition of endothelial cells, when compared to that of KBP, suggesting that the anti-angiogenic activity of KBP is not through inhibiting kallikrein activity or kinin production. KBP competed with (125)I-VEGF for binding to endothelial cells and down-regulated VEGF production in endothelial cells and in the retina of the OIR rat model. CONCLUSION/
INTERPRETATION: Kallikrein-binding protein is a multi-functional serpin, and its vascular activities are independent of its interactions with the kallikrein-kinin system. Inhibition of VEGF binding to its receptors and down-regulation of VEGF expression could represent a mechanism for the vascular activities of KBP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743698     DOI: 10.1007/s00125-003-1085-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  54 in total

Review 1.  The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature.

Authors:  G A Silverman; P I Bird; R W Carrell; F C Church; P B Coughlin; P G Gettins; J A Irving; D A Lomas; C J Luke; R W Moyer; P A Pemberton; E Remold-O'Donnell; G S Salvesen; J Travis; J C Whisstock
Journal:  J Biol Chem       Date:  2001-07-02       Impact factor: 5.157

2.  Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats.

Authors:  D Zhang; P L Kaufman; G Gao; R A Saunders; J X Ma
Journal:  Diabetologia       Date:  2001-06       Impact factor: 10.122

3.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Authors:  D W Dawson; O V Volpert; P Gillis; S E Crawford; H Xu; W Benedict; N P Bouck
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

4.  Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats.

Authors:  J Chao; K X Chai; L M Chen; W Xiong; S Chao; C Woodley-Miller; L X Wang; H S Lu; L Chao
Journal:  J Biol Chem       Date:  1990-09-25       Impact factor: 5.157

5.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules.

Authors:  H Gitay-Goren; S Soker; I Vlodavsky; G Neufeld
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

6.  Antiangiogenic activity of the cleaved conformation of the serpin antithrombin.

Authors:  M S O'Reilly; S Pirie-Shepherd; W S Lane; J Folkman
Journal:  Science       Date:  1999-09-17       Impact factor: 47.728

7.  Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.

Authors:  Yohei Maeshima; Akulapalli Sudhakar; Julie C Lively; Kohjiro Ueki; Surender Kharbanda; C Ronald Kahn; Nahum Sonenberg; Richard O Hynes; Raghu Kalluri
Journal:  Science       Date:  2002-01-04       Impact factor: 47.728

8.  B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects.

Authors:  L Morbidelli; A Parenti; L Giovannelli; H J Granger; F Ledda; M Ziche
Journal:  Br J Pharmacol       Date:  1998-07       Impact factor: 8.739

9.  Expression and characterization of rat kallikrein-binding protein in Escherichia coli.

Authors:  J X Ma; L Chao; G Zhou; J Chao
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

10.  Regulation of cell growth by vitreous humour.

Authors:  G A Lutty; R J Mello; C Chandler; C Fait; A Bennett; A Patz
Journal:  J Cell Sci       Date:  1985-06       Impact factor: 5.285

View more
  19 in total

1.  Plasma kallikrein and diabetic macular edema.

Authors:  Edward P Feener
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 2.  Wnt pathway antagonists and angiogenesis.

Authors:  Bin Zhang; Jian-Xing Ma
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

Review 3.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

4.  Sirt1: A Guardian of the Development of Diabetic Retinopathy.

Authors:  Manish Mishra; Arul J Duraisamy; Renu A Kowluru
Journal:  Diabetes       Date:  2018-01-08       Impact factor: 9.461

5.  Kallikrein-kinin activation by altered vitreous pH: New perspectives for treatment and pathogenesis of diabetic macular edema? : Comment on: Gao BB et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007 Feb;13(2):181-8.

Authors:  O Zeitz; M Keserü
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-06       Impact factor: 3.117

6.  Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family.

Authors:  Bin Zhang; Jose G Abreu; Kevin Zhou; Ying Chen; Yang Hu; Ti Zhou; Xi He; Jian-xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

7.  Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.

Authors:  Shiou-Ling Lu; Chiau-Yuang Tsai; Yueh-Hsia Luo; Chih-Feng Kuo; Wei-Chieh Lin; Yu-Tzu Chang; Jiunn-Jong Wu; Woei-Jer Chuang; Ching-Chuan Liu; Lee Chao; Julie Chao; Yee-Shin Lin
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

8.  Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway.

Authors:  Bin Zhang; Kevin K Zhou; Jian-xing Ma
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

9.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

10.  SERPINA3K prevents oxidative stress induced necrotic cell death by inhibiting calcium overload.

Authors:  Bin Zhang; Jian-xing Ma
Journal:  PLoS One       Date:  2008-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.